NCT07109765View on ClinicalTrials.gov

Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa

RecruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2026

Conditions
Hidradenitis Suppurativa (HS)
Interventions
DRUG

Secukinumab

secukinumab 300 mg weekly for five weeks, followed by 300 mg monthly subcutaneous injection

Trial Locations (1)

100730

RECRUITING

No. 1 Shuai Fu Yuan, Dongcheng District, Beijing, Beijing

All Listed Sponsors
lead

Peking Union Medical College

OTHER